Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Naoki, Kamachi"'
Autor:
Hiroyuki Suzuki, Hideki Iwamoto, Takahiro Seki, Toru Nakamura, Atsutaka Masuda, Takahiko Sakaue, Toshimitsu Tanaka, Yasuko Imamura, Takashi Niizeki, Masahito Nakano, Shigeo Shimose, Tomotake Shirono, Yu Noda, Naoki Kamachi, Miwa Sakai, Kazutoyo Morita, Masamichi Nakayama, Tomoharu Yoshizumi, Ryoko Kuromatsu, Hirohisa Yano, Yihai Cao, Hironori Koga, Takuji Torimura
Publikováno v:
Cancer Communications, Vol 43, Iss 4, Pp 415-434 (2023)
Abstract Background Antiangiogenic tyrosine kinase inhibitors (TKIs) provide one of the few therapeutic options for effective treatment of hepatocellular carcinoma (HCC). However, patients with HCC often develop resistance toward antiangiogenic TKIs,
Externí odkaz:
https://doaj.org/article/b014bbfe6ace4455a5688b7b5212c659
Autor:
Shigeo Shimose, Atsushi Hiraoka, Masatoshi Tanaka, Hideki Iwamoto, Takaaki Tanaka, Kazunori Noguchi, Hajime Aino, Taizo Yamaguchi, Satoshi Itano, Hideya Suga, Takashi Niizeki, Etsuko Moriyama, Tomotake Shirono, Yu Noda, Naoki Kamachi, Shusuke Okamura, Masahito Nakano, Takumi Kawaguchi, Ryoko Kuromatsu, Hironori Koga, Takuji Torimura
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract This study aimed to investigate the clinical characteristics of patients with unresectable hepatocellular carcinoma (HCC), who were eligible for sequential systemic therapy. We evaluated 365 patients with HCC who underwent systemic therapy a
Externí odkaz:
https://doaj.org/article/a8c7a028541d4aafa780bbde3d8cc0b9
Autor:
Tomotake Shirono, Hideki Iwamoto, Takashi Niizeki, Shigeo Shimose, Akira Kajiwara, Hiroyuki Suzuki, Naoki Kamachi, Yu Noda, Shusuke Okamura, Masahito Nakano, Ryoko Kuromatsu, Kenta Murotani, Hironori Koga, Takuji Torimura
Publikováno v:
Hepatology Communications, Vol 6, Iss 9, Pp 2594-2604 (2022)
Abstract In 2013 and 2014, the development of microcatheters with balloons for the 4‐Fr system and new embolization materials provided various options for transarterial chemoembolization (TACE), expanding the range of treatment strategies. At our h
Externí odkaz:
https://doaj.org/article/cb0c660a9fca4c04b06ac51b42f33a78
Autor:
Hiroyuki Suzuki, Hideki Iwamoto, Ken Yamamoto, Mai Tsukaguchi, Toru Nakamura, Atsutaka Masuda, Takahiko Sakaue, Toshimitsu Tanaka, Takashi Niizeki, Shusuke Okamura, Shigeo Shimose, Tomotake Shirono, Yu Noda, Naoki Kamachi, Ryoko Kuromatsu, Toru Hisaka, Hirohisa Yano, Hironori Koga, Takuji Torimura
Publikováno v:
Gastro Hep Advances, Vol 1, Iss 4, Pp 555-562 (2022)
Background and Aims: Hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) progresses with a highly multicentric occurrence (MO) even after radical hepatectomy. Despite several efforts to clarify the pathogenesis of MO, the underlying molecu
Externí odkaz:
https://doaj.org/article/030a69a874c843fc9efe892d239bae68
Autor:
Shigeo Shimose, Atsushi Hiraoka, Masahito Nakano, Hideki Iwamoto, Masatoshi Tanaka, Takaaki Tanaka, Kazunori Noguchi, Hajime Aino, Kei Ogata, Masahiko Kajiwara, Satoshi Itano, Yoshinori Yokokura, Taizo Yamaguchi, Hiroshi Kawano, Norito Matsukuma, Hideya Suga, Takashi Niizeki, Tomotake Shirono, Yu Noda, Naoki Kamachi, Shusuke Okamura, Takumi Kawaguchi, Hironori Koga, Takuji Torimura
Publikováno v:
Cancer Medicine, Vol 10, Iss 23, Pp 8530-8541 (2021)
Abstract Background and Aims Sequential therapy with molecular‐targeted agents (MTAs) is considered effective for unresectable hepatocellular carcinoma (HCC) patients. This study purposed to evaluate the efficacy of sequential therapy with sorafeni
Externí odkaz:
https://doaj.org/article/0894e9642c0c4631b38c4aa5d3985b9c
Autor:
Tomotake Shirono, Hironori Koga, Takashi Niizeki, Hiroaki Nagamatsu, Hideki Iwamoto, Shigeo Shimose, Masahito Nakano, Shusuke Okamura, Yu Noda, Naoki Kamachi, Ryoko Kuromatsu, Etsuyo Ogo, Takuji Torimura
Publikováno v:
Cancer Reports, Vol 5, Iss 8, Pp n/a-n/a (2022)
Abstract Background Invasion beyond inferior vena cava (IVC) to right atrium (RA) is a rare complication in patients with advanced hepatocellular carcinoma (HCC), and results in fatal oncologic emergencies, including pulmonary embolism and right hear
Externí odkaz:
https://doaj.org/article/9e50aff04d9b49cab907b3baa44d8511
Autor:
Hiroyuki Suzuki, Hideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Tomotake Shirono, Yu Noda, Naoki Kamachi, Taizo Yamaguchi, Masahito Nakano, Ryoko Kuromatsu, Hironori Koga, Takumi Kawaguchi
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Recently, a combined regimen of atezolizumab and bevacizumab (AB) treatment has been approved as a first-line treatment in patients with advanced hepatocellular carcinoma (HCC), contributing to prolonged survival. However, we often encounter cases wh
Externí odkaz:
https://doaj.org/article/981db78ffebf4dfc8676a1cbc836d022
Autor:
Masahito Nakano, Ryoko Kuromatsu, Takashi Niizeki, Shusuke Okamura, Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Yu Noda, Naoki Kamachi, Hironori Koga, Takuji Torimura, The Kurume Liver Cancer Study Group of Japan
Publikováno v:
Hepatology Communications, Vol 4, Iss 8, Pp 1218-1228 (2020)
Sorafenib and lenvatinib, as molecular‐targeted agents, constitute effective primary treatment options for advanced hepatocellular carcinoma (HCC). However, the choice of optimal primary treatment agent remains controversial. Here, we aimed to asse
Externí odkaz:
https://doaj.org/article/55d65b545d2046fe92e264d4c8241130
Autor:
Naoki Kamachi, Masahito Nakano, Shusuke Okamura, Takashi Niizeki, Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Yu Noda, Ryoko Kuromatsu, Hironori Koga, Takuji Torimura
Publikováno v:
Cancer Reports, Vol 5, Iss 2, Pp n/a-n/a (2022)
Abstract Background The antitumor effect of a drug is considered to be associated with a decrease in tumor blood flow. Aims We investigated whether the efficacy of lenvatinib (LEN) could be accurately assessed by measuring blood flow in hepatocellula
Externí odkaz:
https://doaj.org/article/4650fc29bd3f44efa295b277c017f6b8
Autor:
Hiroyuki Suzuki, Hideki Iwamoto, Masahito Nakano, Toru Nakamura, Atsutaka Masuda, Takahiko Sakaue, Toshimitsu Tanaka, Dan Nakano, Ryoko Kuromatsu, Takashi Niizeki, Shusuke Okamura, Shigeo Shimose, Tomotake Shirono, Yu Noda, Naoki Kamachi, Hirohisa Yano, Atsushi Kawaguchi, Hironori Koga, Takuji Torimura
Publikováno v:
Translational Oncology, Vol 14, Iss 11, Pp 101201- (2021)
Objective: Although sorafenib, a molecular targeted agent, has survival benefits for advanced hepatocellular carcinoma (HCC) patients, its disease control rate remains limited. To explore the potential for augmenting its antitumor effect, we assessed
Externí odkaz:
https://doaj.org/article/693f8ec225684fd0ac15143ba6a50f1b